Insmed (NASDAQ:INSM) Price Target Raised to $237.00

Key Points

• Barclays raised its price target on Insmed from $231 to $237 and rates the stock "overweight," implying roughly a 44.1% upside from the current price.
• Sell‑side consensus remains positive with an average price target of $212.67 and ratings distribution of 3 Strong Buy, 20 Buy and 1 Sell, giving Insmed an overall "Buy" rating.
• Fundamentals are mixed: INSM traded at $164.47, reported a Q that missed EPS estimates (‑$1.54 vs. est. ‑$1.07) while revenue was roughly in line, the company remains unprofitable with a deeply negative net margin, and insiders sold about 189,651 shares (~$31.5M) in the last quarter.

Insmed (NASDAQ:INSM - Get Free Report) had its price objective lifted by analysts at Barclays from $231.00 to $237.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. Barclays's price target would indicate a potential upside of 44.10% from the company's current price.

Several other research firms also recently commented on INSM. Mizuho lifted their target price on shares of Insmed from $204.00 to $206.00 and gave the stock an "outperform" rating in a research report on Wednesday, March 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Insmed in a research report on Thursday, January 22nd. TD Cowen set a $241.00 price target on shares of Insmed in a research note on Thursday, December 18th. Stifel Nicolaus lifted their price target on shares of Insmed from $205.00 to $208.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Finally, UBS Group reduced their price objective on shares of Insmed from $223.00 to $215.00 and set a "buy" rating on the stock in a research note on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Insmed presently has an average rating of "Buy" and an average price target of $212.67.

Insmed Price Performance

INSM traded up $0.95 on Wednesday, reaching $164.47. The stock had a trading volume of 1,336,291 shares, compared to its average volume of 2,541,482. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The firm has a 50-day moving average of $149.97 and a 200-day moving average of $166.42. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $35.45 billion, a price-to-earnings ratio of -25.65 and a beta of 1.13.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business's revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.32) earnings per share. As a group, sell-side analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Activity

In other news, CFO Sara Bonstein sold 748 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total transaction of $116,942.32. Following the completion of the sale, the chief financial officer directly owned 79,758 shares in the company, valued at $12,469,365.72. This represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael Alexander Smith sold 640 shares of Insmed stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.27, for a total transaction of $100,012.80. Following the transaction, the insider directly owned 56,397 shares of the company's stock, valued at $8,813,159.19. This represents a 1.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 189,651 shares of company stock worth $31,533,654. 3.00% of the stock is owned by company insiders.

Institutional Trading of Insmed

A number of institutional investors have recently bought and sold shares of INSM. CoreCap Advisors LLC bought a new position in shares of Insmed in the 4th quarter worth about $27,000. Reflection Asset Management acquired a new stake in Insmed during the fourth quarter worth approximately $30,000. GraniteShares Advisors LLC acquired a new stake in Insmed during the fourth quarter worth approximately $30,000. CIBC Private Wealth Group LLC increased its holdings in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 53 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in Insmed in the fourth quarter worth approximately $32,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.